1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • September 2016
  • 303 pages
  • Currentpartnering
Report ID: 3679177

Summary

Table of Contents

Search Inside

The Global Cancer Monoclonal Antibody Partnering 2010-2016: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer monoclonal antibody partnering deals
Most active companies in cancer monoclonal antibody partnering
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value

This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

Key benefits

Global Cancer Monoclonal Antibody Partnering Terms & Agreements provides the reader with the following key benefits:

In-depth understanding of cancer monoclonal antibody deal trends since 2010
Access to headline, upfront, milestone and royalty data
Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
Identify most active companies in cancer monoclonal antibody partnering
Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spot the emerging companies in the cancer monoclonal antibody area

Report scope

Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2010
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 360 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2010

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 360 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?


Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of cancer monoclonal antibody deal trends since 2010
Access to headline, upfront, milestone and royalty data
Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
Identify the most active companies engaged in cancer monoclonal antibody partnering
Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024

  • $ 22000
  • Industry report
  • April 2017
  • by Datamonitor Healthcare

Introduction Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic ...

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • April 2017
  • by GlobalData

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025 Summary Cystic fibrosis (CF), which has been given a the diagnostic code E84 from The International Classification of Diseases, ...

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Summary Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological ...

Nash: Kol Insight [2017]

June 2017 $ 9015

Car-t Disease Outlook [2017]

June 2017 $ 8355

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.